Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

The aim of this review is to outline emerging biomarkers that can serve as diagnostic tools to identify non-cirrhotic chronic hepatitis B (CHB) patients who could safely discontinue nucleos(t)ide analogues (NAs) before HBsAg loss. Regarding possible predictors of post-NAs outcomes, a number of studi...

Full description

Bibliographic Details
Main Authors:	Margarita Papatheodoridi, George Papatheodoridis
Format:	Article
Language:	English
Published:	MDPI AG 2020-02-01
Series:	Cells
Subjects:	discontinuation nucleos(t)ide analogues hepatitis b hbsag hbcrag relapse retreatment remission hbsag loss
Online Access:	https://www.mdpi.com/2073-4409/9/2/493

Similar Items

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)

Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
by: Chen-Te Huang, et al.
Published: (2024-04-01)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
by: Bei Jiang, et al.
Published: (2022-12-01)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
by: Peipei Wang, et al.
Published: (2023-01-01)

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
by: E K Ibragimov, et al.
Published: (2019-02-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
by: Milan J. Sonneveld, et al.
Published: (2023-08-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

Trend patterns of HBsAg kinetics in chronic hepatitis B patients during nucleos(t)ide analogue therapy based on ARMA models
by: Hsien-Chung Yu, et al.
Published: (2023-06-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B
by: Zhan-Qing Zhang, et al.
Published: (2017-12-01)

Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up
by: Apichat Kaewdech, et al.
Published: (2022-03-01)

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B
by: Linqing Xie, et al.
Published: (2019-07-01)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
by: Tao Li, et al.
Published: (2018-01-01)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
by: Rong-Nan Chien, et al.
Published: (2022-02-01)

Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report
by: Gian Paolo Caviglia, et al.
Published: (2021-11-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued
by: Liao G, et al.
Published: (2022-04-01)

48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients
by: Li Gao, et al.
Published: (2020-05-01)

Hepatitis B virus-related cryoglobulinemia: Clinical characteristics, virological features, and treatment
by: Hong-xiao Han, et al.
Published: (2023-10-01)

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy
by: Chi-Jung Wu, et al.
Published: (2021-08-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B
by: Jie Peng, et al.
Published: (2015-01-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B
by: Fa-Da Wang, et al.
Published: (2022-06-01)

Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation”
by: Yun‐Fan Liaw, et al.
Published: (2022-04-01)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
by: Xizhan Xu, et al.
Published: (2017-07-01)

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
by: Stijn Van Hees, et al.
Published: (2019-07-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

New perspectives of biomarkers for the management of chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2016-12-01)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
by: Broquetas T, et al.
Published: (2022-07-01)

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report
by: Maki Ohkubo, et al.
Published: (2023-12-01)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
by: Lina Wu, et al.
Published: (2021-02-01)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
by: Wei Y, et al.
Published: (2019-09-01)

Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
by: Yuhao Yao, et al.
Published: (2022-11-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Hepatitis B viral factors and treatment responses in chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2013-06-01)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
by: Li Liu
Published: (2020-02-01)

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection
by: Fangfang Sun, et al.
Published: (2022-11-01)